• Publications
  • Influence
The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update.
TLDR
This guideline covers the definition and classification of urticaria, taking into account the recent progress in identifying its causes, eliciting factors and pathomechanisms, and outlines evidence-based diagnostic and therapeutic approaches for the different subtypes ofUrticaria. Expand
The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria
TLDR
This guideline covers the definition and classification of urticaria, taking into account the recent progress in identifying its causes, eliciting factors and pathomechanisms, and outlines evidence‐based diagnostic and therapeutic approaches for the different subtypes ofUrticaria. Expand
EAACI/GA2LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria
TLDR
This guideline covers the definition and classification of urticaria, taking into account the recent progress in identifying its causes, eliciting factors, and pathomechanisms, and outlines evidence‐based diagnostic approaches for different subtypes ofUrticaria. Expand
Unmet clinical needs in chronic spontaneous urticaria. A GA2LEN task force report 1
TLDR
A GA2LEN task force report concluded that chronic spontaneous urticaria is a “hidden epidemic” that needs to be addressed to address the unmet clinical needs of patients. Expand
The EAACI/GA 2 LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update
TLDR
This guideline covers the definition and classification of urticaria, taking into account the recent progress in identifying its causes, eliciting factors and pathomecha. Expand
Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis.
TLDR
Clinical experience from more than 1250 injections in 51 patients over four years indicates that omalizumab is a rapidly acting, highly effective and safe drug in CSU and CindU patients, and the recommendation of current EAACI/GA(2)LEN/EDF/WAO guideline for the management of urticaria is supported. Expand
H1‐antihistamines: inverse agonism, anti‐inflammatory actions and cardiac effects
This review addresses novel concepts of histamine H1‐receptor function and attempts to relate them to the anti‐inflammatory effects of H1‐antihistamines. Furthermore, the molecular mechanismsExpand
The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria.
TLDR
Administration of omalizumab attenuates the multiple effects of IgE to maintain and enhance mast cell activities and hence reduces the ability of mast cells to manifest inflammatory mechanisms in patients with CSU. Expand
EAACI/GA²LEN/EDF/WAO guideline: management of urticaria
TLDR
This guideline has a profound impact on the quality of life and effective treatment is, therefore, required and the recommended first line treatment is new generation, nonsedating H1‐antihistamines, and second‐line therapies should be added to the antihistamine treatment. Expand
Pharmacology of Antihistamines
TLDR
The newer second-generation H1-antihistamines are safer, cause less sedation and are more efficacious and three drugs widely used for symptomatic relief in urticaria, desloratadine, levocetirizine and fexofenadine are highlighted in this review. Expand
...
1
2
3
4
5
...